Anixa Biosciences Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Anixa Biosciences Inc. has filed its annual 10-K report for the fiscal year ended October 31, 2023, detailing its operations and financial standing.</b>

AI Summary

Anixa Biosciences Inc (ANIX) filed a Annual Report (10-K) with the SEC on January 16, 2024. Anixa Biosciences Inc. filed its 10-K report for the fiscal year ending October 31, 2023. The company's primary business is in Pharmaceutical Preparations, SIC code 2834. Anixa Biosciences was formerly known as ITUS Corp and COPYTELE INC. The company's principal executive offices are located at 3150 Almaden Expressway, Suite 250, San Jose, CA 95118. The filing covers the fiscal period from November 1, 2022, to October 31, 2023.

Why It Matters

For investors and stakeholders tracking Anixa Biosciences Inc, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Anixa Biosciences' financial health, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. Understanding the company's historical structure, including its former names ITUS Corp and COPYTELE INC., provides context for its evolution and current business focus in the pharmaceutical preparations sector.

Risk Assessment

Risk Level: low — Anixa Biosciences Inc shows low risk based on this filing. The filing is a standard 10-K annual report, which typically contains routine financial and operational information without immediate, significant market-moving news.

Analyst Insight

Investors should review the detailed financial statements and risk factors within the 10-K to understand Anixa Biosciences' current financial position and potential challenges.

Key Numbers

• 2023-10-31 — Fiscal Year End (Conformed period of report)
• 2024-01-16 — Filing Date (Filed as of date)
• 2022-11-01 — Fiscal Year Start (Reporting period)
• 001-37492 — SEC File Number (SEC file number)

Key Players & Entities

• Anixa Biosciences Inc. (company) — Filer name
• ITUS Corp (company) — Former company name
• COPYTELE INC (company) — Former company name
• 2834 (dollar_amount) — Standard Industrial Classification
• 3150 Almaden Expressway, Suite 250 (company) — Business address
• San Jose (company) — Business address city
• CA (company) — Business address state
• 95118 (company) — Business address zip

Forward-Looking Statements

• Anixa Biosciences will continue to report significant research and development expenses in its next fiscal year. (Anixa Biosciences Inc.) — high confidence, target: 2024-10-31

FAQ

Industry Context

Anixa Biosciences Inc. operates within the Pharmaceutical Preparations industry, focusing on the development and commercialization of therapies.

Regulatory Implications

The company is subject to standard SEC regulations for public companies, including the requirement to file annual reports on Form 10-K.

What Investors Should Do

1. Review the full 10-K filing for detailed financial statements and management's discussion and analysis.
2. Analyze the company's stated business objectives and any disclosed research and development activities.
3. Assess the company's historical financial performance and compare it to industry benchmarks.

Year-Over-Year Comparison

This filing represents the annual report for the fiscal year ending October 31, 2023, providing updated financial and operational data compared to previous filings.

Key Financial Figures

• $0.01 — ge on Which Registered: Common Stock, $0.01 par value ANIX The NASDAQ Stock Mar
• $4.08 — ommon stock on the NASDAQ on such date ($4.08): $ 120,568,574 . On January 16, 2024
• $210,000 — ober 31, 2023, we derived approximately $210,000 of revenue from these activities). We h

Filing Documents

• form10-k.htm (10-K) — 1358KB
• ex10-10.htm (EX-10.10) — 1KB
• ex19.htm (EX-19) — 73KB
• ex23-1.htm (EX-23.1) — 4KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 16KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• ex99-1.htm (EX-99.1) — 22KB
• ex10-10_001.jpg (GRAPHIC) — 323KB
• 0001493152-24-002453.txt (&nbsp;) — 6589KB
• anix-20231031.xsd (EX-101.SCH) — 31KB
• anix-20231031_cal.xml (EX-101.CAL) — 39KB
• anix-20231031_def.xml (EX-101.DEF) — 165KB
• anix-20231031_lab.xml (EX-101.LAB) — 318KB
• anix-20231031_pre.xml (EX-101.PRE) — 249KB
• form10-k_htm.xml (XML) — 1073KB

Business

Business 2 Item 1A. Risk Factors 10 Item 1B. Unresolved Staff Comments 29 Item 1C. Cybersecurity 29 Item 2.

Properties

Properties 30 Item 3. Legal Proceedings 30 Item 4. Mine Safety Disclosures 30 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 30 Item 6. [Reserved] 31 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 31 Item 7A. Quantitative and Qualitative Disclosures about Market Risk 36 Item 8. Financial 36 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 36 Item 9A. Controls and Procedures 36 Item 9B. Other Information 37 PART III Item 10. Directors, Executive Officers and Corporate Governance 37 Item 11. Executive Compensation 37 Item 12. Security 37 Item 13. Certain Relationships and Related Transactions, and Director Independence 37 Item 14. Principal Accounting Fees and Services 38 PART IV Item 15. Exhibits, Financial Statement Schedules 38 Item 16. Form 10-K Summary 39 i CAUTIONARY Information included in this Annual Report on Form 10-K (this "Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our ac

View Full Filing

View this 10-K filing on SEC EDGAR